Nova Eye Medical (EYE) Discussion, page-949

Not sure there is a risk of something slipping, but I could definitely see them wanting to include unaudited results in the presentation in early August. Too hard to tell, the company is clearly more focused on running the business rather than trying to pump the share price with fluffy announcements (for good reason - this company doesn't need to!). Obviously FY23 results won't really include iTrack Advance performance due to how recently this device was FDA approved (so I am not expecting a rerate based on those numbers) but I am very interested in the commentary we get. Most likely will need to wait for audited results in late August before we get a more detailed outlook and commentary from the company. December will be the big month for numbers